POU5F1 and prostate carcinoma: Moreover, recent studies have demonstrated overexpression of OCT3/4A in patients with hepatocellular carcinoma in prostate cancer, lung cancer, hepatocellular carcinoma, and breast cancer and also in vivo models of prostate cancer (60–62).